Dulaglutide

This article examines the use of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in clinical trials for the treatment of type 2 diabetes. We’ll explore its effectiveness in managing blood glucose levels, potential benefits for liver health, and its safety profile compared to other diabetes medications. The trials discussed investigate dulaglutide’s impact on various aspects of diabetes management, including glycemic control, weight loss, and cardiovascular outcomes.

Related diseases and areas:

• Metabolic syndrome
• Diabetes mellitus
• Multiple sclerosis
• Renal transplant

Dupilumab

This article explores the use of Dupilumab, a biologic medication, in various clinical trials. Dupilumab is being studied for its effectiveness in treating conditions such as eosinophilic esophagitis, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and asthma. These trials aim to assess the drug’s efficacy, safety, and long-term outcomes in different patient populations.

Related diseases and areas:

• Chronic rhinosinusitis with…
• Chronic rhinosinusitis with…
• Asthma
• Neurodermatitis
• Dermatitis
• Eosinophilic gastritis

Dutasteride

Dutasteride, a medication used to treat benign prostatic hyperplasia (BPH) and male pattern baldness, has been the subject of several clinical trials. These studies aim to evaluate its safety, efficacy, and potential applications in various prostate-related conditions. This article summarizes key findings from recent clinical trials investigating dutasteride’s use in different formulations and treatment scenarios.

Related diseases and areas:

• Salivary gland cancer
• Prostate cancer

Duvakitug

Duvakitug, also known as TEV-48574, is an investigational drug being studied for the treatment of moderate to severe ulcerative colitis and Crohn’s disease. These conditions are types of inflammatory bowel disease (IBD) that cause inflammation in the digestive tract. Clinical trials are currently underway to evaluate the effectiveness, safety, and long-term effects of Duvakitug in adult patients with these conditions. The studies aim to determine the optimal dosing and assess various measures of disease improvement.

Related diseases and areas:

• Crohn’s disease
• Colitis ulcerative

DUVELISIB

Duvelisib (also known as Copiktra or IPI-145) is an oral dual inhibitor of phosphoinositide-3-kinase-delta and gamma (PI3K-δ,γ), which has shown promising results in the treatment of various hematologic malignancies. This article explores how duvelisib is being used in clinical trials to treat conditions such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), peripheral T-cell lymphoma (PTCL), and other types of non-Hodgkin lymphoma (NHL). Clinical trials are investigating duvelisib as both a monotherapy and in combination with other treatments, examining its efficacy, safety, and potential to overcome resistance to previous therapies.

Dyp688

A groundbreaking clinical trial is underway to investigate the potential of DYP688, a new drug designed to treat metastatic uveal melanoma (MUM) and other melanomas with specific genetic mutations. This study aims to evaluate the safety, tolerability, and effectiveness of DYP688 in patients with these challenging forms of cancer. The trial consists of two phases and includes different patient groups, offering hope for those who have limited treatment options.

Related diseases and areas:

• Skin cancer
• Uveal melanoma

E.coli Polysaccharide

A clinical trial is underway to evaluate the effectiveness of E. coli Polysaccharide (OM-89) in reducing antibiotic consumption for patients with neurogenic bladder and recurrent urinary tract infections (UTIs). This study aims to compare the use of OM-89 against a placebo in patients with spinal cord injuries, focusing on antibiotic use, UTI incidence, hospitalization rates, and quality of life over a two-year period.

Related diseases and areas:

• Neurogenic bladder

E2814

E2814 is an investigational drug currently being studied in clinical trials for its potential to treat Alzheimer’s disease. This article provides an overview of the ongoing research into E2814, including its safety, efficacy, and potential benefits for patients with early-stage Alzheimer’s and those at risk for inherited forms of the disease.

Related diseases and areas:

• Dementia Alzheimer’s type

Ebastine

Ebastine, a histamine H1 receptor antagonist, is being studied in several clinical trials for its potential benefits in treating various conditions. This article examines the use of Ebastine in clinical trials for irritable bowel syndrome (IBS), metastatic castration-resistant prostate cancer, and urticaria. We’ll explore the drug’s effectiveness, dosage, and potential side effects across different medical applications.

Related diseases and areas:

• Hypersensitivity
• Seasonal allergy
• Conjunctivitis allergic
• Hormone-refractory prostate…
• Irritable bowel syndrome

Eclitasertib

Eclitasertib, also known as SAR443122, is an investigational drug currently being studied in clinical trials for the treatment of moderate to severe ulcerative colitis. This article explores the ongoing research, potential benefits, and important information about Eclitasertib in clinical trials for patients with this inflammatory bowel disease.

Related diseases and areas:

• Colitis ulcerative

Ecoo15

Clinical trials are underway to evaluate the effectiveness of a new vaccine called ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli (E. coli) disease in older adults. This vaccine, which contains the active substance ECOO15 among others, is being tested in adults aged 60 and older with a history of urinary tract infections. The trials aim to assess the vaccine’s ability to prevent serious E. coli infections and its safety profile.

Related diseases and areas:

• Influenza
• Escherichia urinary tract i…
• Escherichia infection

Ecoo16

Clinical trials are underway to evaluate the effectiveness of a new vaccine called ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli (E. coli) disease in older adults. This vaccine, which contains the active substance ECOO16 among others, is being tested in adults aged 60 and older who have a history of urinary tract infections. The trials aim to assess the vaccine’s ability to prevent serious E. coli infections, its safety profile, and its impact on patients’ quality of life.

Related diseases and areas:

• Escherichia infection
• Influenza
• Escherichia urinary tract i…

Ecoo18A

Recent clinical trials are exploring the potential of ExPEC9V, a novel vaccine containing the ECOO18A component, in preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. These studies focus on evaluating the vaccine’s efficacy, safety, and immunogenicity in adults aged 60 and older, particularly those with a history of urinary tract infections. The trials aim to demonstrate the vaccine’s ability to reduce the incidence of invasive E. coli infections and improve the quality of life for vulnerable populations.

Related diseases and areas:

• Influenza
• Escherichia infection
• Escherichia urinary tract i…

Ecoo1A

Clinical trials are underway to evaluate the effectiveness of ExPEC9V, a new vaccine designed to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in older adults. These studies focus on adults aged 60 and above, particularly those with a history of urinary tract infections, as they are at higher risk for invasive E. coli infections. The trials aim to assess the vaccine’s ability to stimulate immune responses and protect against various forms of E. coli-related illnesses, including urinary tract infections and more severe invasive diseases.

Related diseases and areas:

• Escherichia urinary tract i…
• Influenza
• Escherichia infection

Ecoo2

This article discusses clinical trials investigating the use of ExPEC9V vaccine, which contains the active substance ECOO2, for preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in adults aged 60 and older. The trials aim to assess the vaccine’s efficacy, safety, and immune response, particularly in individuals with a history of urinary tract infections.

Related diseases and areas:

• Escherichia infection
• Escherichia urinary tract i…
• Influenza

Ecoo25B

ExPEC9V is an investigational vaccine being studied for its potential to prevent invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in older adults. This article summarizes key information from two clinical trials evaluating the safety, efficacy, and immunogenicity of ExPEC9V in adults aged 60 and older, particularly those with a history of urinary tract infections. The trials aim to assess how well ExPEC9V can protect against serious E. coli infections when given alone or alongside a flu vaccine.

Related diseases and areas:

• Influenza
• Escherichia urinary tract i…
• Escherichia infection

Ecoo4

Clinical trials are currently underway to assess the effectiveness of a new vaccine called ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli (E. coli) disease. This vaccine, which contains the active substance ECOO4 among others, is being tested in adults aged 60 and older who have a history of urinary tract infections. The trials aim to determine if ExPEC9V can safely reduce the occurrence of serious E. coli infections and related complications in this high-risk population.

Related diseases and areas:

• Escherichia infection
• Influenza
• Escherichia urinary tract i…

Ecoo6A

Recent clinical trials have been exploring the potential of a new vaccine called ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. This vaccine, which contains the active substance ECOO6A among others, is being tested in adults aged 60 and older with a history of urinary tract infections. The trials aim to evaluate the vaccine’s efficacy, safety, and ability to stimulate an immune response against various strains of E. coli that can cause serious infections outside the intestinal tract.

Related diseases and areas:

• Escherichia infection
• Influenza
• Escherichia urinary tract i…

Ecoo75

This article discusses clinical trials investigating the use of ExPEC9V, a vaccine containing the active substance ECOO75 (among others), for preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in older adults. The trials aim to assess the vaccine’s efficacy, safety, and immune response in individuals aged 60 and above, particularly those with a history of urinary tract infections.

Related diseases and areas:

• Influenza
• Escherichia infection
• Escherichia urinary tract i…

Ecopipam Hydrochloride

Ecopipam Hydrochloride is an investigational drug being studied in clinical trials for its potential in treating Tourette’s Disorder and its effects on cardiac repolarization. These trials aim to assess the efficacy, safety, and tolerability of Ecopipam in various patient populations, including children, adolescents, and adults. The studies also evaluate the drug’s impact on heart function, providing crucial information for its development as a potential treatment option.

Related diseases and areas:

• Tourette’s disorder

Eculizumab

Eculizumab, also known by its brand name Soliris, is a monoclonal antibody medication that has been the subject of numerous clinical trials for various medical conditions. This article explores the use of eculizumab in clinical trials for conditions such as kidney transplantation, neuromyelitis optica spectrum disorder (NMOSD), generalized myasthenia gravis (gMG), and others. We’ll examine the drug’s potential benefits, safety profile, and effectiveness across different patient populations.

Related diseases and areas:

• Glycogen storage disease ty…
• Chronic hepatitis C
• Paroxysmal nocturnal haemog…
• Hepato-lenticular degeneration
• Gaucher’s disease type I
• Duchenne muscular dystrophy

Edg-5506

EDG-5506 is an investigational drug currently being studied in clinical trials for its potential to help people with muscular dystrophies, particularly Becker muscular dystrophy. This article explores the ongoing research on EDG-5506, including its mechanism of action, safety profile, and how it’s being tested in various clinical trials.

Related diseases and areas:

• Becker’s muscular dystrophy
• Muscular dystrophy
• Glycogen storage disease ty…

Efanesoctocog Alfa

Efanesoctocog alfa, also known as BIVV001, is an innovative drug being studied in clinical trials for the treatment of hemophilia A. This article summarizes key information about ongoing trials evaluating the safety, efficacy, and long-term effects of efanesoctocog alfa in patients with hemophilia A. The trials aim to assess how well this new therapy can prevent and treat bleeding episodes, improve joint health, and enhance quality of life for people living with this bleeding disorder.

Related diseases and areas:

• Factor VIII deficiency

Efavirenz

Efavirenz, also known by brand names Sustiva and Stocrin, is an antiretroviral medication commonly used to treat HIV. Recent clinical trials have been exploring its potential uses beyond HIV treatment, including as a possible therapy for Alzheimer’s disease. This article summarizes key findings from several clinical trials investigating different aspects of efavirenz, from its pharmacokinetics to its effects on brain function and cholesterol metabolism.

Related diseases and areas:

• Dementia Alzheimer’s type

Efepoetin Alfa

Efepoetin Alfa, a novel long-acting erythropoietin-hybrid protein, is currently being studied in clinical trials for its potential in treating anemia, particularly in patients with chronic kidney disease. These trials aim to evaluate the drug’s effectiveness, safety, and tolerability in various patient populations, including healthy volunteers and those undergoing dialysis. The studies compare Efepoetin Alfa to existing treatments and assess its ability to improve hemoglobin levels and overall patient outcomes.

Related diseases and areas:

• Anaemia of chronic disease

Efinopegdutide

Efinopegdutide, also known as MK-6024, HM12525A, or JNJ-64565111, is a promising drug currently being studied in clinical trials for its potential in treating various liver conditions, particularly nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). These trials aim to evaluate the drug’s safety, efficacy, and how well patients tolerate it. The studies focus on efinopegdutide’s ability to reduce liver fat content, improve liver function, and its effects on body weight and other metabolic parameters.

Efmoroctocog Alfa

Efmoroctocog Alfa, also known as Eloctate, is an extended half-life factor VIII product being studied in clinical trials for the treatment of hemophilia A. These trials aim to evaluate its effectiveness in preventing and treating bleeding episodes, improving quality of life, and addressing challenges like inhibitor formation in patients with this rare blood clotting disorder.

Related diseases and areas:

• Factor VIII deficiency
• Factor IX deficiency

Efpegerglucagon

Efpegerglucagon, also known as HM15136, is being studied in clinical trials as a potential treatment for children aged 2 and older with Congenital Hyperinsulinism (CHI). This rare genetic condition causes excessive insulin production, leading to dangerously low blood sugar levels. The ongoing research aims to evaluate the safety, tolerability, and effectiveness of Efpegerglucagon in managing CHI symptoms and improving patients’ quality of life.

Related diseases and areas:

• Congenital hyperinsulinaemi…
• Hyperinsulinism

Efruxifermin

Efruxifermin (EFX) is an innovative drug currently undergoing clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH). These conditions are serious liver diseases associated with fat accumulation, inflammation, and fibrosis. The ongoing studies aim to evaluate the safety and efficacy of EFX in patients with various stages of liver disease, from non-cirrhotic to compensated cirrhosis. The trials are designed to assess improvements in liver health, metabolic parameters, and overall patient outcomes.

Related diseases and areas:

• Hepatic fibrosis
• Hepatic cirrhosis

Eftilagimod Alfa

Eftilagimod Alfa, also known as IMP321 or efti, is an innovative immunotherapy drug currently being studied in clinical trials for various types of cancer. This article explores the use of Eftilagimod Alfa in combination with other treatments, its potential benefits, and ongoing research efforts to improve cancer treatment outcomes.

Related diseases and areas:

• Head and neck cancer metast…
• HER2 negative breast cancer
• Non-small cell lung cancer …
• Breast cancer stage IV
• Soft tissue sarcoma

Eftrenonacog Alfa

This article discusses an 18-month clinical trial investigating the effectiveness of Eftrenonacog Alfa (ALPROLIX) in improving joint health for patients with hemophilia A and B. The study aims to assess joint outcomes using ultrasound technology, clinical evaluations, and patient-reported measures. This low-intervention trial provides valuable insights into the long-term effects of ALPROLIX on joint health and quality of life for individuals with hemophilia.

Related diseases and areas:

• Factor VIII deficiency
• Factor IX deficiency

Efzofitimod

Efzofitimod is an experimental drug being studied in clinical trials for various lung conditions, including systemic sclerosis-related interstitial lung disease (SSc-ILD), pulmonary sarcoidosis, and severe pneumonia related to COVID-19. These trials aim to evaluate the safety, efficacy, and tolerability of efzofitimod in patients with these challenging respiratory conditions.

Related diseases and areas:

• Pulmonary sarcoidosis

EGANELISIB

EGANELISIB (also known as IPI-549) is an innovative drug currently being investigated in multiple clinical trials for various types of cancer. As a first-in-class, oral immuno-oncology medication, EGANELISIB works by targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma. This mechanism helps to overcome immune suppression in the tumor microenvironment, potentially making cancer treatments more effective. The drug is being studied both as a monotherapy and in combination with other cancer treatments for conditions including acute myeloid leukemia, solid tumors, triple-negative breast cancer, renal cell carcinoma, and urothelial carcinoma. These trials aim to evaluate the safety, tolerability, and efficacy of EGANELISIB in patients with advanced cancers who need new treatment options.

Related diseases and areas:

• Acute myeloid leukaemia ref…
• Acute myeloid leukaemia rec…
• Myelodysplastic syndrome

Eik1003

This article discusses the ongoing clinical trials of EIK1003 (also known as IMP1734), a novel PARP1 selective inhibitor being studied for the treatment of advanced solid tumors. The trials aim to evaluate the safety, tolerability, and effectiveness of EIK1003 as both a monotherapy and in combination with other anti-cancer agents. The study focuses on patients with various types of advanced cancers, including ovarian, breast, prostate, and pancreatic cancers.

Related diseases and areas:

• Neoplasm

Elacestrant

Elacestrant is an emerging drug being studied in clinical trials for the treatment of advanced breast cancer, particularly in patients with estrogen receptor-positive (ER+) and HER2-negative tumors. This article explores the ongoing research and potential benefits of Elacestrant in various clinical settings, including its use as a single agent and in combination with other therapies.

Related diseases and areas:

• HER2 negative breast cancer
• Breast cancer metastatic
• Breast cancer
• Hormone receptor positive b…
• Breast cancer female
• Breast cancer male

Elamipretide Trihydrochloride

Elamipretide Trihydrochloride is currently being studied in clinical trials as a potential treatment for dry age-related macular degeneration (dry AMD). This article explores the ongoing research, focusing on a Phase 3 clinical trial called ReNEW, which aims to evaluate the efficacy, safety, and pharmacokinetics of subcutaneous injections of Elamipretide in patients with dry AMD.

Related diseases and areas:

• Dry age-related macular deg…

Elasomeran

This article explores the use of Elasomeran, a key component in COVID-19 mRNA vaccines, in various clinical trials. These studies aim to assess the vaccine’s effectiveness, immune responses, and potential applications in different populations. The trials cover topics such as comparing high-dose and standard-dose influenza vaccines, investigating immune responses in COVID-19 recovered patients, and evaluating long-term immunity after vaccination.

Related diseases and areas:

• Influenza
• COVID-19

Elebsiran

This article explores the ongoing clinical trials investigating the use of Elebsiran (VIR-2218) for treating chronic hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. Elebsiran is being studied alone and in combination with other therapies to assess its safety, efficacy, and potential to achieve functional cure in patients with these chronic viral liver infections.

Related diseases and areas:

• Chronic hepatitis B

Elenestinib Phosphate

Elenestinib Phosphate, also known as BLU-263, is an investigational drug currently being studied in clinical trials for the treatment of Indolent Systemic Mastocytosis (ISM) and Smoldering Systemic Mastocytosis (SSM). This article explores the ongoing research into Elenestinib Phosphate’s potential to improve outcomes for patients with these rare mast cell disorders.

Related diseases and areas:

• Indolent systemic mastocytosis

Eletriptan

Eletriptan, a second-generation serotonin receptor agonist, has been the subject of several clinical trials exploring its efficacy in treating migraines and other conditions. Originally approved for acute migraine treatment, recent studies have investigated its potential in addressing spinal cord injuries and menstrual migraines. This article summarizes key findings from clinical trials using Eletriptan, highlighting its effectiveness, safety profile, and potential new applications in medical treatment.

Related diseases and areas:

• Spinal cord injury

Elexacaftor

Elexacaftor, a groundbreaking drug used in combination therapy for cystic fibrosis (CF), has shown promising results in various clinical trials. This article explores the impact of elexacaftor-based treatments on different aspects of CF, including lung function, gastrointestinal issues, and overall quality of life for patients across different age groups.

Related diseases and areas:

• Cystic fibrosis

Elezanumab

Elezanumab, also known as ABT-555, is an investigational drug being studied in clinical trials for various neurological conditions. These trials aim to assess the safety and efficacy of Elezanumab in treating acute spinal cord injury, acute ischemic stroke, and multiple sclerosis. The drug is administered through intravenous infusion and is being evaluated for its potential to improve neurological function and promote neuroregeneration in patients with these challenging conditions.

Related diseases and areas:

• Spinal cord injury cervical

Eliglustat Tartrate

Eliglustat tartrate, also known as Genz-112638, is an oral medication being studied in clinical trials for the treatment of Gaucher disease, a genetic disorder that affects the body’s ability to break down certain fats. These trials aim to evaluate the efficacy, safety, and long-term effects of eliglustat tartrate in patients with different types of Gaucher disease, including those who have previously been treated with enzyme replacement therapy.

Related diseases and areas:

• Gaucher’s disease type I
• Gaucher’s disease type III

Elinzanetant

Elinzanetant is an investigational drug being studied for the treatment of vasomotor symptoms (hot flashes) associated with menopause. This article summarizes key information from multiple clinical trials evaluating the efficacy, safety, and pharmacokinetics of elinzanetant in postmenopausal women and other populations experiencing hormone-related hot flashes.

Related diseases and areas:

• Menopausal symptoms
• Sleep disorder
• Autonomic nervous system im…

Elotuzumab

Elotuzumab is an innovative drug being studied in clinical trials for the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. These trials aim to evaluate the safety and effectiveness of elotuzumab alone or in combination with other drugs in patients with relapsed or refractory multiple myeloma. The research explores various dosing regimens and combination therapies to improve outcomes for patients who have limited treatment options.

Related diseases and areas:

• Plasma cell myeloma refractory
• Plasma cell myeloma

Elraglusib

Elraglusib, also known as 9-ING-41, is an investigational drug being studied for the treatment of various types of cancer, including blood cancers and solid tumors. This article explores the ongoing clinical trials of Elraglusib, focusing on its potential benefits for patients with refractory (hard-to-treat) cancers and its use alone or in combination with other chemotherapy drugs.

Related diseases and areas:

• Haematological malignancy
• Neoplasm malignant

Elranatamab

Elranatamab is an innovative bispecific antibody being studied in clinical trials for the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. This article explores the ongoing research into elranatamab’s safety and efficacy across various stages of multiple myeloma, from newly diagnosed to relapsed/refractory cases.

Related diseases and areas:

• Plasma cell myeloma refractory
• Myelodysplastic syndrome
• Plasma cell myeloma
• Non-Hodgkin’s lymphoma
• Acute myeloid leukaemia

Elritercept

Elritercept, also known as KER-050, is an investigational drug being studied in clinical trials for the treatment of myelofibrosis (MF) and myelodysplastic syndromes (MDS). These trials aim to evaluate the safety, tolerability, and efficacy of elritercept in patients with anemia associated with these blood disorders. The studies are exploring elritercept as both a monotherapy and in combination with other treatments, offering hope for improved outcomes in patients with these challenging conditions.

Related diseases and areas:

• Myelofibrosis
• Myelodysplastic syndrome
• Anaemia

ELTANEXOR

Eltanexor is an investigational drug currently being studied in clinical trials for patients with blood cancers that have not responded to previous treatments or have returned after initial improvement. A notable ongoing phase I trial is examining the combination of Eltanexor with another medication called Venetoclax for treating relapsed or refractory myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This study aims to determine the safety, appropriate dosage, and effectiveness of this drug combination. Eltanexor works by trapping tumor-suppressing proteins within cancer cells, potentially causing these cells to die or stop growing, while Venetoclax blocks a protein called BCL-2 that cancer cells need for survival.

Related diseases and areas:

• Acute myeloid leukaemia rec…
• Acute myeloid leukaemia ref…

Eltrombopag

Eltrombopag, a thrombopoietin receptor agonist, is being extensively studied in clinical trials for its potential to treat various blood disorders. This article explores the use of eltrombopag in conditions such as immune thrombocytopenia (ITP), aplastic anemia, and in enhancing platelet engraftment following cord blood transplantation. We’ll delve into the ongoing research, potential benefits, and safety considerations of this promising drug.

Related diseases and areas:

• Immune thrombocytopenia
• Myelodysplastic syndrome